Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00070317 · ClinicalTrials.gov registry record · NA
Lymph Node Mapping and Sentinel Lymph Node Identification in Patients With Stage IB1 Cervical Cancer
A NA study, sponsored by Gynecologic Oncology Group.
- Terminated
- Registry status
- NA
- Development phase
- 102
- Enrollment target
NCT00070317 is a NA study that was terminated before completion, run by Gynecologic Oncology Group. The registered enrollment target is 102 participants.
The verdict
NCT00070317, a NA study, was terminated before completion, sponsored by Gynecologic Oncology Group.
- TERMINATED
- Registry status
- NA
- Development phase
- 102 participants
- Enrollment target
Study Summary
This clinical trial is studying how well lymph node mapping and sentinel lymph node identification work in finding lymph node metastases in patients with stage IB1 cervical cancer. Diagnostic procedures, such as lymph node mapping and sentinel lymph node identification, performed before and during surgery, may improve the ability to detect lymph node metastases in patients who have cervical cancer.
Interventions
- PROCEDURE Lymphangiography
- PROCEDURE Radionuclide Imaging
- PROCEDURE Lymph Node Mapping
- DRUG Isosulfan Blue
- DRUG Methylene Blue
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 102 participants |
| Start Date | 2004-06 |
| Est. Completion | 2013-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00070317
The ClinicalTrials.gov registry entry for NCT00070317 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 102 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gynecologic Oncology Group, which has 154 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Lymphangiography is the first listed.
NCT00070317 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00070317 about?
NCT00070317 is a clinical study titled "Lymph Node Mapping and Sentinel Lymph Node Identification in Patients With Stage IB1 Cervical Cancer". This clinical trial is studying how well lymph node mapping and sentinel lymph node identification work in finding lymph node metastases in patients with stage IB1 cervical cancer. Diagnostic procedures, such as lymph node mapping and sentinel lymph node identification, performed before and during s...
What is the current status of trial NCT00070317?
This trial is currently terminated. It is a NA study. The enrollment target is 102 participants. The study started on 2004-06. Estimated completion is 2013-01.
What interventions are being tested in trial NCT00070317?
The interventions under investigation include: Lymphangiography (PROCEDURE), Radionuclide Imaging (PROCEDURE), Lymph Node Mapping (PROCEDURE), Isosulfan Blue (DRUG), Methylene Blue (DRUG).
Who is sponsoring clinical trial NCT00070317?
This trial is sponsored by Gynecologic Oncology Group, which has 154 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.